Skip to main content

Carlos Molina Cateriano

Institutions of which they are part

Head of group
Stroke research
Vall Hebron Institut de Recerca

Carlos Molina Cateriano

Institutions of which they are part

Head of group
Stroke research
Vall Hebron Institut de Recerca

Projects

Grup de Recerca en Malalties Neurovasculars

IP: Joan Montaner Villalonga
Collaborators: José Alvarez Sabin, Marc Ribó Jacobi, Maria Pilar Delgado Martínez, Carlos Molina Cateriano, Anna Rosell Novel, Estevo Santamarina Pérez, Manuel Quintana Luque
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 50600
Reference: 2005SGR 00614
Duration: 01/01/2006 - 31/12/2008

Impacto de las concentraciones de proteina C reactiva, metaloproteasas de la matriz y plasminogen activador inhibitor-1 (PAI-1) y de determinados polimorfismos de sus genes sobre progresión y complicación de la aterosclerosis intracraneal sintomática.

IP: Carlos Molina Cateriano
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 41400
Reference: PI040438
Duration: 01/01/2005 - 28/12/2007

Influencia de las metaloproteasas de matriz en las complicaciones hemorrágicas tras el tratamiento trombolítico en el ictus isquémico.

IP: Joan Montaner Villalonga
Collaborators: José Alvarez Sabin, Marc Ribó Jacobi, Carlos Molina Cateriano, Manuel Quintana Luque
Funding agency: Instituto de Salud Carlos III
Funding: 33005
Reference: PI020773
Duration: 06/11/2002 - 06/11/2005

Papel de las metaloproteinasas en el desarrollo de edema en la fase aguda de la hemorragia intracerebral y en los fenomenos de reparacion y remodelacion posteriores.

IP: José Alvarez Sabin
Collaborators: Joan Montaner Villalonga, Alex Rovira Cañellas, Carlos Molina Cateriano
Funding agency: Instituto de Salud Carlos III
Funding: 30741.77
Reference: 01/1389
Duration: 17/07/2001 - 31/12/2003

Related news

UMBRELLA, a consortium of over 20 public and private partners, kicks off this week with the aim of revolutionising the entire stroke care pathway in Europe by adopting a holistic approach that covers stroke diagnosis, prevention and care.

The Consortium will create a platform to facilitate a personalised management for stroke patients, enabling a more efficient personalized monitoring and patient follow up.

Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

Related professionals

Laura Doménech Moral

Laura Doménech Moral

Main researcher
Basic, Translational and Clinical Pharmacy Research
Read more
José Raul Herance Camacho

José Raul Herance Camacho

Head of group
Molecular Medical Imaging
Read more
Jesús  Cirbián Franqueira

Jesús Cirbián Franqueira

Predoctoral researcher
Read more
Alejandra Monte Soldado

Alejandra Monte Soldado

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.